Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Dömling A[au]:

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Zak KM et al. Structure. (2017)

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Magiera-Mularz K et al. Angew Chem Int Ed Engl. (2017)

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies? Konstantinidou M et al. Angew Chem Int Ed Engl. (2018)

Search results

Items: 1 to 50 of 159

1.

Artificial Macrocycles.

Abdelraheem EMM, Shaabani S, Dömling A.

Synlett. 2018 Jun;29(9):1136-1151. doi: 10.1055/s-0036-1591975. Epub 2018 May 7.

2.

Rapid approach to complex boronic acids.

Neochoritis CG, Shaabani S, Ahmadianmoghaddam M, Zarganes-Tzitzikas T, Gao L, Novotná M, Mitríková T, Romero AR, Irianti MI, Xu R, Olechno J, Ellson R, Helan V, Kossenjans M, Groves MR, Dömling A.

Sci Adv. 2019 Jul 5;5(7):eaaw4607. doi: 10.1126/sciadv.aaw4607. eCollection 2019 Jul.

3.

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Błaszkiewicz U, Pustuła M, Butera R, Dömling A, Holak TA.

Molecules. 2019 May 30;24(11). pii: E2071. doi: 10.3390/molecules24112071. Review.

4.

Studies on vascular response to full superantigens and superantigen derived peptides: Possible production of novel superantigen variants with less vasodilation effect for tolerable cancer immunotherapy.

Bashraheel SS, AlQahtani AD, Rashidi FB, Al-Sulaiti H, Domling A, Orie NN, Goda SK.

Biomed Pharmacother. 2019 Jul;115:108905. doi: 10.1016/j.biopha.2019.108905. Epub 2019 May 3.

5.

Diverse Isoquinoline Scaffolds by Ugi/Pomeranz-Fritsch and Ugi/Schlittler-Müller Reactions.

Wang Y, Patil P, Kurpiewska K, Kalinowska-Tluscik J, Dömling A.

Org Lett. 2019 May 17;21(10):3533-3537. doi: 10.1021/acs.orglett.9b00778. Epub 2019 Apr 29.

6.

Novel Compounds Targeting the RNA-Binding Protein HuR. Structure-Based Design, Synthesis, and Interaction Studies.

Della Volpe S, Nasti R, Queirolo M, Unver MY, Jumde VK, Dömling A, Vasile F, Potenza D, Ambrosio FA, Costa G, Alcaro S, Zucal C, Provenzani A, Di Giacomo M, Rossi D, Hirsch AKH, Collina S.

ACS Med Chem Lett. 2019 Jan 21;10(4):615-620. doi: 10.1021/acsmedchemlett.8b00600. eCollection 2019 Apr 11.

PMID:
30996806
7.

MCR Scaffolds Get Hotter with 18F-Labeling.

Zarganes-Tzitzikas T, Clemente GS, Elsinga PH, Dömling A.

Molecules. 2019 Apr 4;24(7). pii: E1327. doi: 10.3390/molecules24071327.

8.

Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.

Al-Qahtani AD, Bashraheel SS, Rashidi FB, O'Connor CD, Romero AR, Domling A, Goda SK.

Biomed Pharmacother. 2019 Apr;112:108725. doi: 10.1016/j.biopha.2019.108725. Epub 2019 Feb 28.

9.

Acoustic Droplet Ejection Enabled Automated Reaction Scouting.

Wang Y, Shaabani S, Ahmadianmoghaddam M, Gao L, Xu R, Kurpiewska K, Kalinowska-Tluscik J, Olechno J, Ellson R, Kossenjans M, Helan V, Groves M, Dömling A.

ACS Cent Sci. 2019 Mar 27;5(3):451-457. doi: 10.1021/acscentsci.8b00782. Epub 2019 Feb 27.

10.

Atorvastatin (Lipitor) by MCR.

Zarganes-Tzitzikas T, Neochoritis CG, Dömling A.

ACS Med Chem Lett. 2019 Feb 7;10(3):389-392. doi: 10.1021/acsmedchemlett.8b00579. eCollection 2019 Mar 14.

11.

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.

Neochoritis CG, Kazemi Miraki M, Abdelraheem EMM, Surmiak E, Zarganes-Tzitzikas T, Łabuzek B, Holak TA, Dömling A.

Beilstein J Org Chem. 2019 Feb 20;15:513-520. doi: 10.3762/bjoc.15.45. eCollection 2019.

12.

Stapled Peptides Inhibitors: A New Window for Target Drug Discovery.

Ali AM, Atmaj J, Van Oosterwijk N, Groves MR, Dömling A.

Comput Struct Biotechnol J. 2019 Feb 19;17:263-281. doi: 10.1016/j.csbj.2019.01.012. eCollection 2019. Review.

13.

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment.

AlQahtani AD, O'Connor D, Domling A, Goda SK.

Biomed Pharmacother. 2019 May;113:108750. doi: 10.1016/j.biopha.2019.108750. Epub 2019 Mar 5. Review.

14.

Oligomeric protein interference validates druggability of aspartate interconversion in Plasmodium falciparum.

Batista FA, Bosch SS, Butzloff S, Lunev S, Meissner KA, Linzke M, Romero AR, Wang C, Müller IB, Dömling ASS, Groves MR, Wrenger C.

Microbiologyopen. 2019 Feb 28:e779. doi: 10.1002/mbo3.779. [Epub ahead of print]

15.

A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Skalniak L, Twarda-Clapa A, Neochoritis CG, Surmiak E, Machula M, Wisniewska A, Labuzek B, Ali AM, Krzanik S, Dubin G, Groves M, Dömling A, Holak TA.

FEBS J. 2019 Apr;286(7):1360-1374. doi: 10.1111/febs.14774. Epub 2019 Feb 16.

PMID:
30715803
16.

Tetrazoles via Multicomponent Reactions.

Neochoritis CG, Zhao T, Dömling A.

Chem Rev. 2019 Feb 13;119(3):1970-2042. doi: 10.1021/acs.chemrev.8b00564. Epub 2019 Feb 1.

17.

Automated and Accelerated Synthesis of Indole Derivatives on a Nano-Scale.

Shaabani S, Xu R, Ahmadianmoghaddam M, Gao L, Stahorsky M, Olechno J, Ellson R, Kossenjans M, Helan V, Dömling A.

Green Chem. 2019 Jan 21;21(2):225-232. doi: 10.1039/C8GC03039A. Epub 2018 Dec 21.

PMID:
30686932
18.

Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.

Iordanidou D, Zarganes-Tzitzikas T, Neochoritis CG, Dömling A, Lykakis IN.

ACS Omega. 2018 Nov 30;3(11):16005-16013. doi: 10.1021/acsomega.8b02749. Epub 2018 Nov 27.

19.

Macrocycles: MCR synthesis and applications in drug discovery.

Abdelraheem EMM, Shaabani S, Dömling A.

Drug Discov Today Technol. 2018 Nov;29:11-17. doi: 10.1016/j.ddtec.2018.06.008. Epub 2018 Jul 12. Review.

PMID:
30471668
20.

The Catalytic Enantioselective Ugi Four-Component Reactions.

Shaabani S, Dömling A.

Angew Chem Int Ed Engl. 2018 Dec 10;57(50):16266-16268. doi: 10.1002/anie.201811129. Epub 2018 Nov 15. Review.

21.

Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.

Wójcik M, Eleftheriadis N, Zwinderman MRH, Dömling ASS, Dekker FJ, Boersma YL.

Eur J Med Chem. 2019 Jan 1;161:93-100. doi: 10.1016/j.ejmech.2018.10.027. Epub 2018 Oct 15.

PMID:
30343193
22.

Production of "biobetter" glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.

AlQahtani AD, Al-Mansoori L, Bashraheel SS, Rashidi FB, Al-Yafei A, Elsinga P, Domling A, Goda SK.

Eur J Pharm Sci. 2019 Jan 15;127:79-91. doi: 10.1016/j.ejps.2018.10.014. Epub 2018 Oct 19.

PMID:
30343151
23.

A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).

Shaabani S, Huizinga HPS, Butera R, Kouchi A, Guzik K, Magiera-Mularz K, Holak TA, Dömling A.

Expert Opin Ther Pat. 2018 Sep;28(9):665-678. doi: 10.1080/13543776.2018.1512706. Epub 2018 Sep 10. Review.

PMID:
30107136
24.

Multicomponent Reaction Based Synthesis of 1-Tetrazolylimidazo[1,5- a]pyridines.

Kurhade S, Diekstra E, Sutanto F, Kurpiewska K, Kalinowska-Tłuścik J, Dömling A.

Org Lett. 2018 Jul 6;20(13):3871-3874. doi: 10.1021/acs.orglett.8b01452. Epub 2018 Jun 26.

25.

Triglyceride profiling in adipose tissues from obese insulin sensitive, insulin resistant and type 2 diabetes mellitus individuals.

Al-Sulaiti H, Diboun I, Banu S, Al-Emadi M, Amani P, Harvey TM, Dömling AS, Latiff A, Elrayess MA.

J Transl Med. 2018 Jun 26;16(1):175. doi: 10.1186/s12967-018-1548-x.

26.

Artificial Macrocycles as IL-17A/IL-17RA Antagonists.

Wang W, Groves MR, Dömling A.

Medchemcomm. 2018 Jan 1;9(1):22-26. doi: 10.1039/C7MD00464H. Epub 2017 Oct 25.

27.

Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment.

Rashidi FB, AlQhatani AD, Bashraheel SS, Shaabani S, Groves MR, Dömling A, Goda SK.

PLoS One. 2018 Apr 26;13(4):e0196254. doi: 10.1371/journal.pone.0196254. eCollection 2018.

28.

Guide for Selection of Relevant Cell Lines During the Evaluation of new Anti-Cancer Compounds.

Ruiz-Moreno AJ, Torres-Barrera P, Velázquez-Paniagua M, Dömling A, Velasco-Velázquez MA.

Anticancer Agents Med Chem. 2018;18(8):1072-1081. doi: 10.2174/1871520618666180220120544. Review.

PMID:
29697026
29.

Identification of a non-competitive inhibitor of Plasmodium falciparum aspartate transcarbamoylase.

Lunev S, Bosch SS, Batista FA, Wang C, Li J, Linzke M, Kruithof P, Chamoun G, Dömling ASS, Wrenger C, Groves MR.

Biochem Biophys Res Commun. 2018 Mar 11;497(3):835-842. doi: 10.1016/j.bbrc.2018.02.112. Epub 2018 Feb 21.

30.

Synthesis of Highly Substituted Imidazole Uracil Containing Molecules via Ugi-4CR and Passerini-3CR.

Madhavachary R, Zarganes-Tzitzikas T, Patil P, Kurpiewska K, Kalinowska-Tłuścik J, Dömling A.

ACS Comb Sci. 2018 Apr 9;20(4):192-196. doi: 10.1021/acscombsci.7b00145. Epub 2018 Feb 26.

31.

Diastereoselective One Pot Five-Component Reaction toward 4-(Tetrazole)-1,3-Oxazinanes.

Chandgude AL, Narducci D, Kurpiewska K, Kalinowska-Tłuścik J, Dömling A.

RSC Adv. 2017;7(79):49995-49998. doi: 10.1039/C7RA07392E. Epub 2017 Oct 26.

32.

Discovery of chromenes as inhibitors of macrophage migration inhibitory factor.

Kok T, Wapenaar H, Wang K, Neochoritis CG, Zarganes-Tzitzikas T, Proietti G, Eleftheriadis N, Kurpiewska K, Kalinowska-Tłuścik J, Cool RH, Poelarends GJ, Dömling A, Dekker FJ.

Bioorg Med Chem. 2018 Mar 1;26(5):999-1005. doi: 10.1016/j.bmc.2017.12.032. Epub 2017 Dec 24.

33.

Two-Step Macrocycle Synthesis by Classical Ugi Reaction.

Abdelraheem EMM, Khaksar S, Kurpiewska K, Kalinowska-Tłuścik J, Shaabani S, Dömling A.

J Org Chem. 2018 Feb 2;83(3):1441-1447. doi: 10.1021/acs.joc.7b02984. Epub 2018 Jan 24.

34.

Library-to-Library Synthesis of Highly Substituted α-Aminomethyl Tetrazoles via Ugi Reaction.

Patil P, Mishra B, Sheombarsing G, Kurpiewska K, Kalinowska-Tłuścik J, Dömling A.

ACS Comb Sci. 2018 Feb 12;20(2):70-74. doi: 10.1021/acscombsci.7b00137. Epub 2018 Jan 4. Review.

35.

Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Konstantinidou M, Zarganes-Tzitzikas T, Magiera-Mularz K, Holak TA, Dömling A.

Angew Chem Int Ed Engl. 2018 Apr 23;57(18):4840-4848. doi: 10.1002/anie.201710407. Epub 2018 Feb 23. Review.

36.

Ugi Multicomponent Reaction Based Synthesis of Medium-Sized Rings.

Abdelraheem EMM, Madhavachary R, Rossetti A, Kurpiewska K, Kalinowska-Tłuścik J, Shaabani S, Dömling A.

Org Lett. 2017 Nov 17;19(22):6176-6179. doi: 10.1021/acs.orglett.7b03094. Epub 2017 Oct 30.

37.

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.

Skalniak L, Zak KM, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, Pyrc K, Dömling A, Dubin G, Holak TA.

Oncotarget. 2017 Aug 7;8(42):72167-72181. doi: 10.18632/oncotarget.20050. eCollection 2017 Sep 22.

38.

Artificial Macrocycles as Potent p53-MDM2 Inhibitors.

Estrada-Ortiz N, Neochoritis CG, Twarda-Clapa A, Musielak B, Holak TA, Dömling A.

ACS Med Chem Lett. 2017 Sep 20;8(10):1025-1030. doi: 10.1021/acsmedchemlett.7b00219. eCollection 2017 Oct 12.

39.

Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Shaabani S, Neochoritis CG, Twarda-Clapa A, Musielak B, Holak TA, Dömling A.

Medchemcomm. 2017 May 1;8(5):1046-1052. doi: 10.1039/C7MD00058H. Epub 2017 Mar 15.

40.

AnchorQuery: Rapid online virtual screening for small-molecule protein-protein interaction inhibitors.

Koes DR, Dömling A, Camacho CJ.

Protein Sci. 2018 Jan;27(1):229-232. doi: 10.1002/pro.3303. Epub 2017 Oct 24.

41.

Concise Synthesis of Tetrazole Macrocycle.

Abdelraheem EMM, de Haan MP, Patil P, Kurpiewska K, Kalinowska-Tłuścik J, Shaabani S, Dömling A.

Org Lett. 2017 Oct 6;19(19):5078-5081. doi: 10.1021/acs.orglett.7b02319. Epub 2017 Sep 13.

42.

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Magiera-Mularz K, Skalniak L, Zak KM, Musielak B, Rudzinska-Szostak E, Berlicki Ł, Kocik J, Grudnik P, Sala D, Zarganes-Tzitzikas T, Shaabani S, Dömling A, Dubin G, Holak TA.

Angew Chem Int Ed Engl. 2017 Oct 23;56(44):13732-13735. doi: 10.1002/anie.201707707. Epub 2017 Sep 26.

43.

Photoactivation provides a mechanistic explanation for pan-assay interference behaviour of 2-aminopyrroles in lipoxygenase inhibition.

Guo H, Eleftheriadis N, Rohr-Udilova N, Dömling A, Dekker FJ.

Eur J Med Chem. 2017 Oct 20;139:633-643. doi: 10.1016/j.ejmech.2017.07.047. Epub 2017 Jul 24.

PMID:
28843180
44.

A Systematic Protein Refolding Screen Method using the DGR Approach Reveals that Time and Secondary TSA are Essential Variables.

Wang Y, van Oosterwijk N, Ali AM, Adawy A, Anindya AL, Dömling ASS, Groves MR.

Sci Rep. 2017 Aug 24;7(1):9355. doi: 10.1038/s41598-017-09687-z.

45.

Cysteine Isocyanide in Multicomponent Reaction: Synthesis of Peptido-Mimetic 1,3-Azoles.

Vishwanatha TM, Kurpiewska K, Kalinowska-Tłuścik J, Dömling A.

J Org Chem. 2017 Sep 15;82(18):9585-9594. doi: 10.1021/acs.joc.7b01615. Epub 2017 Aug 25.

46.

Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.

Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA.

Structure. 2017 Aug 1;25(8):1163-1174. doi: 10.1016/j.str.2017.06.011. Review.

47.

With unprotected amino acids to tetrazolo peptidomimetics.

Madhavachary R, Wang Q, Dömling A.

Chem Commun (Camb). 2017 Jul 27;53(61):8549-8552. doi: 10.1039/c7cc03370b.

48.

Two-Step Synthesis of Complex Artificial Macrocyclic Compounds.

Madhavachary R, Abdelraheem EMM, Rossetti A, Twarda-Clapa A, Musielak B, Kurpiewska K, Kalinowska-Tłuścik J, Holak TA, Dömling A.

Angew Chem Int Ed Engl. 2017 Aug 28;56(36):10725-10729. doi: 10.1002/anie.201704426. Epub 2017 Aug 1.

49.

2-Nitrobenzyl Isocyanide as a Universal Convertible Isocyanide.

Chandgude AL, Li J, Dömling A.

Asian J Org Chem. 2017 Jul;6(7):798-801. doi: 10.1002/ajoc.201700177. Epub 2017 Mar 31.

50.

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, Skalniak L, Dömling A, Dubin G, Holak TA.

J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.

PMID:
28613862

Supplemental Content

Loading ...
Support Center